DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20204364

Nitrofurantoin and Fosfomycin for the CRE and MDR uropathogens: are the choices still same?

Nusrat Perween, Asfia Sultan, Anees Akhtar, Fatima Khan, Meher Rizvi, Haris M. Khan, Manzoor Ahmad

Abstract


Background: Urinary tract infection (UTI) is one of the most common bacterial infections, affecting 150 million people each year worldwide with substantial clinical and financial burden. With upcoming multi drug resistance (MDR) and carbepenem resistance among uropathogens there is urgent need to explore other new or old treatment options like nitrofurantoin and fosfomycin trometamol.

Methods: This is a cross-sectional (descriptive study) conducted over 6 month’s period from October 2019 to March 2020. Out of 9045 urine samples, 1788 (19.8%) were positive (1721 samples with single organism and 67 samples with 2 organisms). Total 1855 isolates were identified and antimicrobial susceptibility was performed by Kirby-Bauer method and VITEK 2 system. Methicillin‑resistant Staphylococcus aureus (MRSA), vancomycin resistant enterococci (VRE), multi drug resistance (MDR) and metallo‑beta‑lactamases (MBL) production was detected.

Results: E. coli 41.8% was found commonest followed by enterococcus species (21.6%). Methicillin resistance was 66% while 1.8% were VRE. 429 (34.5%) were CRE (carbapenem resistant enterobacteriales) out of which, 154 (36%) were MBL while 188 (44%) were detected as serine carbapenemase producers via modified carbapenem inactivation method (mCIM) and EDTA-modified carbapenem inactivation method (eCIM) testing. Among 742 (40%) MDR, fosfomycin was effective in 611 (82.3%) while 331 (77.1%) of the CRE isolates were susceptible to fosfomycin.

Conclusions: Fosfomycin should be reserved for MDR and nitrofurantoin should be used cautiously otherwise resistance will increase to these drugs in the coming days.


Keywords


MDR, Uropathogens, Fosfomycin, Nitrofurantoin

Full Text:

PDF

References


Fair RJ, Tor Y. Antibiotics and bacterial resistance in the 21st century. Perspect Medicin Chem. 2014:6:25-64.

Farajnia S, Alikhani MY, Ghotaslou R, Naghili B, Nakhlband A. Causative agents and antimicrobial susceptibilities of urinary tract infections in the Northwest of Iran. Int J Infect Dis. 2009;13:140-4.

Nickel JC. Management of urinary tract infections: Historical perspective and current strategies: Part 2 – modern management. J Urol. 2005;173 (1):27-32.

Sharma N, Gupta A, Walia G, Bakhshi R. Pattern of antimicrobial resistance of Escherichia coli isolates from urinary tract infection patients: A three year retrospective study. J Appl Pharm Sci. 2016;6:62-5.

Naber KG, Schito G, Botto H, Palou J, Mazzei T. Surveillance study in Europe and Brazil on clinical aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): Implications for empiric therapy. Eur Urol. 2008;54:1164-75.

Mandell GL, Bennett JE, Dolin R. Mandell, Douglas and Benett's. Principles and Practice of Infectious Diseases. Philadelphia: Elsevier Churchill Livingstone. 6th ed. 2005;2789-95.

Patel, SS, Balfour JA, and Bryson HM. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections. Drugs. 1997;53:637-56.

Winn WC, Allen SD, Allen S, Janda WM, Koneman E W, Schreckenberger PC. Woods Koneman's Textbook of Diagnostic Microbiology. 6th ed. Philadelphia: Lippincott Williams and Wilkins. 2006.

Collee JG, Fraser AG, Marmion BP. Mackie And Mccartney Practical Medical Microbiology. 14th ed. Elsevier. 1996.

Tille P. Bailey & Scott's Diagnostic Microbiology. 13th ed. St. Louis, Missouri:Elsevier, 2014.

Charan J, Biswas T. How to Calculate Sample Size for Different Study Designs in Medical Research? Indian J Psychol Med. 2013;35(2):121-6.

Clinical and Laboratory Standards Institute, editor. Performance Standards for Antimicrobial Susceptibility Test: 30th Edition. Wayne, PA: Committee for Clinical Laboratory Standards; 2020.

Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.

Prakash D, Saxena RS. Distribution and Antimicrobial Susceptibility Pattern of Bacterial Pathogens Causing Urinary Tract Infection in Urban Community of Meerut City, India. ISRN Microbiology. 2013;749629.

Sood S, Gupta R. Antibiotic resistance pattern of community acquired uropathogens at a tertiary care hospital in Jaipur, Rajasthan. Ind J Comm Med. 2012;37:39-44.

George CE, Norman G, Ramana GV, Mukherjee D, Rao T. Treatment of uncomplicated symptomatic urinary tract infections: Resistance patterns and misuse of antibiotics. J Family Med Prim Care. 2015;4:416-21.

Agbagwa OE, IfeanachoEmeka JU. The Prevalence of UTI Pathogens in Urine Specimen Obtained from a Hospital in Rivers State Nigeria. J Microbiol Res. 2015;5 (5):143-8.

Das A, Banerjee T. Prevalence of Urinary Tract Infections and Susceptibily Pattern of Uropathogens in Women of Reproductive age Group from North India. J Advances Med. 2015;4 (1-2).

Patel HB, Soni ST, Bhagyalaxmi A, Patel NM. Causative agents of urinary tract infections and their antimicrobial susceptibility patterns at a referral center in Western India. J Family Med Prim Care. 2019;8 (1):154-9.

Banerjee S, Sengupta M, Sarker TK. Fosfomycin susceptibility among multidrug-resistant, extended-spectrum beta-lactamase-producing, carbapenem-resistant uropathogens. Ind J Urol. 2017;33 (2):149-54.

Pardeshi P. Prevalence of urinary tract infections and current scenario of antibiotic susceptibility pattern of bacteria causing UTI. Ind J Microbiol Res. 2018;5 (3):334-8.

Maraki S, Samonis G, Rafailidis PI, Vouloumanou EK, Mavromanolakis E and Falagas ME. Susceptibility of Urinary Tract Bacteria to Fosfomycin. Antimicrob Agents Chemo. 2009;4508-10.

Sultan A, Rizvi M, Khan F, Sami H, Shukla I, Khan HM. Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urol Ann. 2015;7:26-30.

Rizvi M, Khan F, Shukla I, Malik A, Shaheen. Rising prevalence of antimicrobial resistance in urinary tract infections during pregnancy: Necessity for exploring newer treatment options. J Lab Physicians. 2011;3:98-103.

Al-Zahrani J, Al Dossari K, Gabr AH, Ahmed AF, Al Shahrani SA, Al-Ghamdi S. Antimicrobial resistance patterns of Uropathogens isolated from adult women with acute uncomplicated cystitis. BMC Microbiol. 2019;19:237.

Pouladfar G, Basiratnia M, Anvarinejad M, Abbasi P, Amirmoezi F, Zare S. The antibiotic susceptibility patterns of uropathogens among children with urinary tract infection in Shiraz. Medicine. 2017;96:37.

Moyo SJ, Aboud S, Kasubi M, Maselle SY. Bacterial isolates and drug susceptibility patterns of urinary tract infection among pregnant women at Muhimbili National Hospital in Tanzania. Tanzan. J Health Res. 2010;12:236-40.

Gupta V, Rani H, Singla N, Kaistha N, Chander J. Determination of extended-spectrum β-lactamases and ampc production in uropathogenic isolates of Escherichia coli and susceptibility to fosfomycin. J Lab Physicians. 2013;5:90-3.

Rajenderan S, Balaji V, Anandan S, Sahni RD, Tansarli GS, Falagas ME. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against Gram-negative clinical isolates in South India: A prospective study. PLoS One. 2014;9:103253.

Sahni RD, Balaji V, Varghese R, John J, Tansarli GS, Falagas ME. Evaluation of fosfomycin activity against uropathogens in a fosfomycin-naive population in South India: A prospective study. Future Microbiol. 2013;8:675-80.

Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: A systematic review. Lancet Infect Dis. 2010;10:43-5.